Launch Date: 11/01/21

Aprazer Healthcare Launched XGRAF (Tacrolimus Capsules ) which is used for the prophylaxis of organ rejection in adults and paediatric patients receiving kidney transplant, liver transplant and heart transplant, in combination with other immunosuppressant’s.

Launch Date: 19/12/20

Aprazer Healthcare Launched MEROAXIS (Meropenem Inj) which is a medication indicated for the treatment of susceptible infections including intra-abdominal infections, meningitis, respiratory tract infections (Including cystic fibrosis patients) septicemia, skin infections, urinary tract infections and infections in immune-compromised patients.

Launch Date: 07/12/20

Aprazer Healthcare Launched HQKAST (Hydroxychloroquine), which is a medication indicated for the treatment of Malaria, Whipple’s Disease, Rheumatoid Disease

Launch Date: 31/10/20

Aprazer Healthcare Launched CAPEKAST (Capecitabine) which is a medication indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated.

Launch Date: 17/10/20

Aprazer Healthcare Launched Lenvakast (Lenvatinib) which is a medication indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). LENVAKAST is indicated for the 1st-line treatment of patients with unresectable hepatocellular carcinoma. LENVAKAST is also indicated for Renal Cell Carcinoma. LENVAKAST is also indicated for Endometrial Carcinoma.

Launch Date: 29/09/2020

Aprazer Healthcare Launched Lenakast (Lenalidomide) which is a medication indicated for the treatment of Myelodysplastic Syndromes Multiple Myeloma in combination with Dexamethasone, Mantle Cell Lymphoma and  Follicular Lymphoma or Marginal Zone Lymphoma.

Launch Date: 31/08/20

Aprazer Healthcare Launched TAMIKAST (Oseltamivir) which is a medication indicated for the treatment of Influenza Infection and Prophylaxis

Launch Date: 29/08/20

Aprazer Healthcare Launched INLYBEST (Axitinib) which is a medication indicated for the treatment of Advanced Renal Cell Carcinoma and Hepatocellular carcinoma.

Launch Date: 10/08/20

Aprazer Healthcare Launched OCABEST (Obeticholic Acid ) which is a medication indicated for the treatment of Primary Biliary Cirrhosis who have not responded to UDCA treatment.

Launch Date: 13-07-2020

Aprazer Healthcare Launched INDENZA ( ENZALUTAMIDE ) which is a  medication indicated for the treatment of castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer (mCSPC) .